Business
Practice ManagementMalpractice ConsultHealth Law & Policy
Media
Case-Based Peer PerspectivesInvestigator Perspectives Medical World NewsPodcastsUrology Medical PerspectivesUTv VideosPeer ExchangeSpecial ReportVirtual Tumor BoardInsightsMedcastPeers & Perspectives
Conferences
Conference ListingConference Previews Conference Recaps
Publications
Urology Times JournalEditorial Advisory BoardUrologists in Cancer CareSupplements and Featured PublicationsClinical Forums Recaps
More
CME/CE
Resources
Begin Your Journey: Tackling BurnoutSponsored MediaLive EventsInteractive ToolsJob BoardPartnersSponsored ResourcesTreatment Landscape Evolutions

Subscribe

  • Business
  • Media
  • Conferences
  • Publications
  • CME/CE
  • Resources
  • Subscribe
  • Benign Conditions
  • Benign Prostatic Hyperplasia
  • Bladder Cancer
  • Female Urology
  • Genitourinary Cancers
  • Genomic Testing
  • Hormone Therapy
  • Kidney Cancer
  • Kidney Stones
    • Challenging Anatomy
  • Men's Health
  • Next-Generation Imaging
  • OAB and Incontinence
    • Voiding Dysfunction
  • Pediatrics
  • Prostate Cancer
    • Controveries in Urologic Cancer
    • Drug Therapy
  • Sexual Dysfunction
  • UTUC
  • Urologic Surgery
    • Cosmetic Surgery
Spotlight -
Peer Exchange|
Peers and Perspectives|
Case-Based Peer Perspectives|
Urology Times Journal
Advertisement

Ralph J. Miller Jr, MD

Advertisement

Articles by Ralph J. Miller Jr, MD

Ralph Miller, MD, on the state of HIFU in prostate cancer

ByRalph J. Miller Jr, MD
December 2nd 2024

"Most of the published data about HIFU tended to be with relatively short-term follow-up," says Ralph J. Miller Jr, MD.

Advertisement

Latest Updated Articles



    Advertisement
    Advertisement

    Trending on Urology Times

    1

    FDA grants clearance to Hugo robotic-assisted surgery system for urologic procedures

    2

    Apalutamide is linked to fewer CNS-related conditions in patients with nmCRPC

    3

    Prostate MRI is linked with higher sensitivity, NPV vs micro-ultrasound in pilot study

    4

    Michael Cookson, MD, discusses new strategies for treatment intensification in prostate cancer

    5

    BOND-003: Cretostimogene yields durable 24-month responses in high-grade NMIBC

    • About Us
    • Advertise
    • Editorial
    • Contact Us
    • Job Board
    • Terms and Conditions
    • Privacy
    • Do not sell my Personnal Information
    Contact Info

    259 Prospect Plains Rd, Bldg H
    Cranbury, NJ 08512

    609-716-7777

    Brand Logo

    © 2025 MJH Life Sciences®

    All rights reserved.

    Home
    About Us
    News
    Contact Us